GEN Exclusives

More »

GEN News Highlights

More »
Feb 2, 2007

CSL Behring and Bayer Extend Agreement Related to Hemophilia

  • CSL Behring reached an agreement with Bayer HealthCare to continue the supply and distribution of a therapy for the treatment of hemophilia A. Bayer will provide Helixate® recombinant coagulation Factor VIII to CSL Behring through 2017.

    Additionally, Bayer was granted a license to intellectual property related to recombinant FVIII. At the same time, the companies settled outstanding litigation relating to the supply of recombinant Factor VIII.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?